Repare Therapeutics Inc. Common Shares (RPTX) Dividend History

Repare Therapeutics Inc. is a biotechnology company focused on discovering and developing targeted therapies for cancer patients. Leveraging its precision medicine platform, Repare aims to identify genetic vulnerabilities in cancer cells and develop novel treatments to improve patient outcomes. The company’s approach involves advanced synthetic lethality strategies to create therapies tailored to specific genetic profiles of tumors.

7171 Frederick Banting, Saint-Laurent, A8, H4S 1Z9
Phone: (857) 412-7018
Website: https://www.reparerx.com

Dividend History

Repare Therapeutics Inc. Common Shares currently does not pay dividends

Company News

Companion Diagnostic Markets Report 2025-2029: Diagnostic Firms Jockey for Position as Pharmaceutical Partnerships Flourish, Discover the Impact of AI

The report examines the rapidly evolving companion diagnostics market, driven by advancements in artificial intelligence and the formation of innovative partnerships between diagnostic and pharmaceutical companies. It provides insights into market trends, growth opportunities, and the impact of emerging technologies across 18 countries and 4 regions.

GlobeNewswire Inc.

Featured Companies: A ILMN TEM TMO
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics

Canadian Nuclear Laboratories (CNL) is collaborating with Repare Therapeutics and Defence Therapeutics on research projects through its CNRI-H program, which aims to accelerate the development of targeted radiopharmaceuticals in Canada.

GlobeNewswire Inc.
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Zacks Investment Research

Featured Companies: ALXO ANVS CGEN
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

Featured Companies: KYMR
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?

Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research

Featured Companies: EBS

Dividend data last updated 06/07/2025 09:42:18 UTC